Compare iShares MSCI Australia ETF (EWA) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Australia ETF vs Sana Biotechnology Inc — how do they compare? iShares MSCI Australia ETF trades at $28.62 (market cap $1.17B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: iShares MSCI Australia ETF is the larger of the two by market cap, and iShares MSCI Australia ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Australia ETF for 61 Days and Sana Biotechnology Inc for 23 Days on average.
| EWA | SANA | |
|---|---|---|
Market Cap | $1.17B | $836.71M |
Volume | 2,121,231 | 4,507,444 |
Sector | Broad Market / Factor | Health |
52-Week High | $30.43 | $5.92 |
52-Week Low | $24.95 | $2.68 |
Typical Hold Time | 61 Days | 23 Days |
Enterprise Value | — | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The iShares MSCI Australia ETF (EWA) trades at $28.23, showing no change over the past 24 hours. Technical indicators are predominantly bearish, with moving averages signaling a sell and oscillators neutral. Recent news highlights institutional selling by Squarepoint Ops LLC and broader Australian market pressures from inflation concerns, though some analysts see upside potential tied to commodity exposure.
The outlook is mixed; EWA offers exposure to Australia's commodity-driven economy with potential for gains if raw material prices rise, but faces headwinds from inflation and monetary policy tightening. Key risks include economic sensitivity to global demand and market volatility. Analyst sentiment is divided, with some targeting over 20% upside.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
